Private Wegovy (semaglutide) programme in London, consultant-led from screening to off-ramp.
Genuine MHRA-licensed Wegovy pens from a GPhC-registered UK pharmacy. A named consultant, a proper dose ladder, a registered dietitian and a written plan for the day you stop - not a form on an app.
Indicative pricing
What a private Wegovy programme costs in London.
Indicative ranges across UK private providers and MHRA-licensed pharmacies.
In short
£300–£400, with a monthly consultant review included.
| Programme step | Indicative range | Typical schedule | Review cadence |
|---|---|---|---|
| Initial consultant consultation | £150–£250 | 30–45 min | Same visit |
| Month 1 - starter (0.25 mg pen) | £180–£220 | Weekly dose | Pen dispatched |
| Month 2–4 - titration (0.5 / 1.0 / 1.7 mg) | £220–£320 | Weekly dose | Monthly review |
| Maintenance month (2.4 mg pen) | £300–£400 | Weekly dose | Monthly review |
| Registered dietitian add-on (per session) | £80–£150 | 45–60 min | Same week |
| DEXA body composition scan | £200–£300 | 15–20 min | Same day |
Prices vary by consultant, by pharmacy and by the dose step you are on - the 2.4 mg pen costs more than the 0.25 mg starter.
The problem
The real drug, titrated properly, with a plan for when you stop.
Wegovy is the most-copied, most-compounded and most-mis-prescribed medicine in the UK right now. We fix the three places where private programmes usually fail - supply, titration and the exit plan.
-
Getting the real drug
Genuine MHRA-licensed Wegovy pens from a GPhC-registered UK pharmacy - no compounded semaglutide, no unlicensed vials, no unknown potency.
-
Titrating without the sickness
A consultant who will hold you at 0.5 or 1.0 mg for longer if you need it - rather than a rigid four-week ladder that leaves you nauseated and stopping.
-
Life after stopping
STEP 4 showed two-thirds of the weight comes back within a year of stopping without support. Every programme includes a written off-ramp before you start.
When it helps
When Wegovy is the right tool.
The situations we see most, plus the one red flag that means investigation before anyone writes a prescription.
-
BMI ≥ 30 with weight to lose
The core MHRA licence - adults with a BMI of 30 or more, as an adjunct to diet, activity and behavioural change.
-
BMI ≥ 27 with a comorbidity
Overweight with type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea - the licence extends to this group.
-
Plateau after diet and training
Structured diet and resistance work has stalled. Wegovy can restart loss where the biology is fighting you.
-
PCOS-related weight and insulin resistance
Where weight loss will help ovulation, cycle control and metabolic risk - often used alongside a gynaecology plan.
-
Pre-bariatric optimisation
Reducing weight and hepatic fat before bariatric or major elective surgery to lower anaesthetic and surgical risk.
-
Weight regain after previous loss
The commonest pattern in the clinic - big loss on a diet, steady regain over 12–24 months, biology winning. Wegovy is a tool for that.
-
Cardiometabolic risk reduction
Semaglutide reduces major cardiovascular events in the SELECT trial in overweight or obese adults with established cardiovascular disease.
-
Red flag: unexplained rapid loss
Unexplained weight loss, night sweats or a change in bowel habit is not an indication for Wegovy - it needs investigation first.
Dose ladder
Every step of the Wegovy dose, in plain language.
What each dose step actually does, when to hold instead of climb, and the practical points - injection technique, storage, travel and the plan for coming off.
-
0.25 mg - starter (weeks 0–4)
The very first dose is not a treatment dose. It is deliberately sub-therapeutic to let the gut settle and to keep nausea, reflux and fatigue manageable.
-
0.5 mg - titration (weeks 4–8)
The first therapeutic step. Some weight loss appears here; if side-effects are heavy the dose is held at 0.5 mg rather than pushed up on schedule.
-
1.0 mg - titration (weeks 8–12)
The dose many people used to sit on for months in the older diabetes licence. Meaningful loss typically arrives on this step for most.
-
1.7 mg - titration (weeks 12–16)
The pre-maintenance step. Nausea often eases once your gut has adjusted; if it does not, the consultant holds you at 1.7 mg rather than force the last step.
-
2.4 mg - maintenance
The full licensed maintenance dose in the STEP trials. Most people reach it around week 16 and stay on it while they are actively losing.
-
Injection technique
Weekly subcutaneous injection into abdomen, thigh or upper arm - rotate the site each week. A short teaching session with a nurse or dietitian is included.
-
Storage and travel
Unused pens live in the fridge (2–8 °C). Once in use, a pen tolerates room temperature for a defined window - enough for a holiday with a cool bag and a travel letter we can write.
-
Off-ramp and step-down
Stopping cold-turkey is the pattern most likely to regain. We plan a lower-dose maintenance or a taper alongside a protein and training plan before you stop.
Safety and side-effects
What to expect - honestly, before you start.
Wegovy is one of the most-studied weight-loss medicines in the world. The things worth planning are the gut side-effects on titration, the contraindications the app-only clinics miss, and the muscle-mass loss that comes with any big deficit.
-
Nausea and vomiting
The commonest side-effect, especially on titration steps. Small portions, low-fat meals, hydration and slow eating help; the dose is held rather than pushed if it is not settling.
-
Constipation and reflux
Slower gastric emptying means constipation and reflux are common. Fibre, water, movement and short-term PPI cover deal with most of it.
-
Gallstones with rapid loss
Rapid weight loss of any cause raises gallstone risk. Sudden right upper abdominal pain after fatty food deserves a same-week ultrasound.
-
Pancreatitis (rare)
A rare but reported association with GLP-1 medicines. Severe, persistent central abdominal pain radiating to the back is a same-day A&E symptom, not a wait-and-see one.
-
Muscle-mass loss
Up to a quarter of the weight lost on any big deficit is lean tissue. Protein targets (roughly 1.2–1.6 g/kg) and resistance training are the counterweight - built into the programme.
-
MTC / MEN2 - contraindication
A personal or family history of medullary thyroid cancer or MEN2 is a contraindication because of a thyroid C-cell tumour signal in rodent studies. We screen for this before prescribing.
-
Hypoglycaemia if on insulin or sulfonylurea
Wegovy on its own does not usually cause hypos. Added to insulin or a sulfonylurea it can - those medicines are reviewed and dose-adjusted before you start.
-
Pregnancy - contraindication + washout
Wegovy is contraindicated in pregnancy and while trying to conceive. A two-month washout is advised before conception; we plan contraception with you if that matters.
-
Red flags to call about
Severe or persistent vomiting, severe abdominal pain, jaundice, a swollen tender calf or a lump in the neck - call the clinic the same day or go to A&E if you cannot.
Your Wegovy plan
Your programme, in four parts. Read the last one first.
The written plan the consultant sends you keeps to the same shape - so you always know where you are on it.
A quiet reminder
The most useful page in a Wegovy plan is the one about stopping - read it before you start.
If you would like us to talk you through the plan before your first review, just ask.
- 01 Intake
Intake summary and eligibility
Why you are a candidate - BMI, comorbidities, previous treatments - and a clear note of the contraindications and cautions we have screened out.
- 02 Dose ladder
Dose ladder chosen for you
The planned titration from 0.25 mg through 2.4 mg with the intended review points, and the conditions under which we hold or slow the ladder.
- 03 Monitoring
Monitoring plan - weight, waist, HbA1c
What we track at each 4-weekly review: weight, waist, blood pressure, HbA1c, lipids, side-effects and a check on muscle mass, sleep and mood.
- 04 Off-ramp
Off-ramp and maintenance strategy
Read this first: how we plan to step you down or maintain when you are ready to stop, and the lifestyle scaffolding that keeps the weight off.
Recognised by major UK insurers
Note - weight-loss medicines including Wegovy are usually excluded from UK private medical insurance and are self-pay.
Frequently asked
Everything we get asked about Wegovy.
Quick answers on what it is, how much you can expect to lose, side-effects, cost and what happens when you stop.
-
What is Wegovy?
Wegovy is the branded, MHRA-licensed weight-loss form of semaglutide - a weekly subcutaneous injection made by Novo Nordisk. It is licensed for chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related comorbidity such as type 2 diabetes, hypertension or sleep apnoea.
-
How does it work?
Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, dampens appetite signalling in the brain and improves blood-glucose handling - you feel full sooner, stay full longer and think about food less. It works alongside diet and activity, not instead of them.
-
Can I get Wegovy on the NHS?
NHS access is tight. NICE guidance TA875 restricts Wegovy to specialist Tier 3 or 4 weight-management services, usually for a BMI of 35 or more with a comorbidity, and only for a maximum of two years. Waiting lists for those services are long, which is why most people who want Wegovy in the UK access it privately.
-
How much weight will I lose?
The STEP 1 trial (NEJM 2021) showed an average of about 15% body-weight loss over 68 weeks in adults without diabetes, on top of lifestyle change. Losses are lower in people with type 2 diabetes and vary widely - some lose more, some less. The programme is set up to track your trajectory honestly.
-
What are the side-effects I should plan around?
Nausea, constipation, reflux and fatigue are the common ones and are usually worst on titration steps. Gallstones can appear with rapid loss. Pancreatitis is rare but real. Muscle-mass loss is expected on any big deficit and is why we insist on protein and resistance training.
-
What happens when I stop taking it?
The STEP 4 trial showed that stopping semaglutide is followed by steady weight regain - around two-thirds of the loss back over the next year without support. That is why every Pulse Atlas programme includes a written off-ramp plan: a lower maintenance dose or a taper, alongside protein and resistance-training targets that do the biological work the drug was doing.
Related treatments